1. United Kingdom Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
EKF Diagnostics Holdings plc

EKF Diagnostics Holdings plc

EKDHF
EKF Diagnostics Holdings plcUS flagOther OTC
0.35
USD
- -
- -
149.28MMarket Cap
EKF Diagnostics Holdings plc
EKDHF
(Other OTC)

Recent

price

0.35

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
0.07
0.1
0.1
0.12
0.1
0.07
0.09
0.09
0.09
0.1
0.14
0.18
0.15
0.12
0.11
0.12
Revenue per Share
-0.04
-0.01
0.01
- -
-0.01
-0.09
- -
0.01
0.02
0.01
0.02
0.03
-0.02
0.01
0.01
- -
Basic EPS, GAAP
-0.04
-0.01
- -
- -
-0.02
-0.02
0.02
0.01
0.01
0.01
0.02
0.01
0.01
- -
0.02
0.02
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.01
0.01
0.01
0.01
- -
- -
Dividend per Share
-0.02
-0.01
- -
- -
-0.01
-0.1
-0.09
0.12
0.12
0.13
0.15
0.17
0.12
0.12
0.13
0.13
Book Value per Share
0.03
0.02
0.03
0.02
-0.02
0.01
0.03
0.04
0.05
0.07
0.09
0.12
0.09
0.08
0.1
0.09
Tangible Book Value per Share
98
214
255
272
380
422
446
463
457
454
455
457
457
454
454
448
Basic Weighted Avg Shares
6
22
26
32
37
30
39
42
43
45
65
82
67
53
50
52
Sales/Revenue/Turnover
-5.37
-9.42
0.78
7.55
-5.23
-47.76
-0.85
11.37
28.67
12.88
25.89
26.69
2.67
8.24
12.52
13.53
Operating Margin (%)
1
2
3
4
5
8
5
5
4
4
5
6
7
5
5
5
Depreciation Expense
-3
-3
2
-1
-6
-37
- -
3
10
4
11
16
-10
2
6
2
Net Income, GAAP
- -
- -
- -
247.12
- -
- -
- -
31.74
15.34
28.74
25.86
24.62
- -
- -
- -
64.28
Effective Tax Rate (%)
-52.98
-13.32
7.02
-3.54
-15.33
-123.56
-0.05
6.53
23.76
8.19
17.03
19.37
-15.16
4.47
12.44
4.12
Profit Margin (%)
5
5
6
6
7
-3
7
9
10
14
25
34
20
16
22
23
Working Capital
- -
2
2
2
2
1
1
1
1
1
1
2
1
1
1
1
LT Debt
24
37
39
41
87
47
61
60
64
71
78
95
75
68
73
70
Total Equity
- -
- -
- -
-8.06
- -
- -
- -
4.91
15.96
5.81
15.99
18.15
- -
- -
- -
3.36
Return on Invested Capital (%)
- -
- -
- -
-80.24
- -
- -
- -
22.93
17.3
5.71
16.37
20.47
- -
- -
- -
2.93
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
18.05
6.24
17.26
21.57
-14.86
4.26
11.06
3.66
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.12%
-1.07%
-4.01%
Free Cash Flow
-189.49%
-393.24%
-32.66%
Net Income, GAAP
-1,501.73%
-29%
-66%
Sales/Revenue/Turnover
7.33%
-3.22%
2.73%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
53
2024
- -
- -
- -
- -
50
2025
- -
- -
- -
- -
52

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.01
2024
- -
- -
- -
- -
0.01
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.01
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Lutronic Corp (085370.KS)
Motus GI Holdings, Inc. (MOTS)
CardieX Limited (CDX.AX)
Allmed Solutions Ltd (ALMD.TA)
REMSleep Holdings, Inc. (RMSL)
IRadimed Corporation (IRMD)
Business
EKF Diagnostics Holdings plc is an AIM-listed diagnostics and biotechnology company that develops, manufactures and distributes point-of-care testing devices, central laboratory analyzers and reagents, and life sciences products including enzymes and contract fermentation services; it offers analyzers for hemoglobin, hematocrit, HbA1c, glucose, lactate and beta-hydroxybutyrate (β-HB), such as Hemo Control, Diaspect Tm, Biosen, Quo-Test and Quo-Lab, alongside β-HB LiquiColor reagents, clinical chemistry tests and custom kits for research, biotech and pharmaceutical applications. Founded in 1990 and headquartered in Penarth, near Cardiff, United Kingdom, the company operates manufacturing facilities in the United States and Germany, with a presence in Russia, and distributes products to over 120 countries worldwide targeting hospitals, clinics, blood banks, laboratories and industrial users. In recent developments, EKF reports record hematology analyzer sales with a 60% production increase in the first half of 2025 versus the prior year, secures post-period contract wins worth approximately €4.65 million for hemoglobin analyzers and consumables in Latin America and Africa to be delivered over 12 to 24 months, advances production capacity expansion plans by a further 30% at its Barleben site, achieves 12% growth in β-HB sales driven by partner conversions to own-label products, completes a circa £1 million share buyback acquiring 4.6 million shares, and progresses a five-year strategic plan targeting over £80 million in revenues and number one positions in point-of-care hematology and ketone testing by 2029, while winding down low-margin clinical chemistry lines.

Company News

APIChatGPT

  • defenseworld.net

    EKF Diagnostics (EKDHF) Projected to Post Earnings on Tuesday

  • defenseworld.net

    EKF Diagnostics (OTCMKTS:EKDHF) Stock Price Up 0.9% – Should You Buy?

  • seekingalpha.com

    EKF Diagnostics Holdings plc (EKDHF) Q2 2025 Earnings Call Transcript